Synergetics (SURG) FQ1 results beat on a per share basis, but come up just shy on revenue, despite an 11.6% Y/Y jump in profit. Top line sales benefited from ongoing demand for its ophthalmic and neurosurgical products across all major market segments, particularly in its disposable product unit, which accounted for 82% of the company's total FQ1 sales.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs